Preparation and Evaluation of Novel Sugar Dendritic Gd-DTPA Complexes for MRI Contrast Agents and Phospha Sugars for Anti-Tumour Agents

Abstract:

Novel Sugar Dendritic Gd(III)-DTPA complexes for MRI Contrast Agents (CAs) were prepared and evaluated by in vitro and in vivo methods. The sugar dendritic MRI contrast agents had a good blood vessel pool character and drew blood vessels and liver cancers remarkably clearer and longer time enough than the clinically being used Gd(III)-DTPA complex (Magnevist). Phospha sugar derivatives or phosphorus heterocyclic derivatives provided by functional groups such as epoxide, bromide, etc., were prepared and evaluated by the MTT in vitro method. These phospha sugar derivatives showed excellent anti-proliferative effects of leukemia cell lines, e.g., K562 and U937, as well as solid cancer cells in fashions of (i) higher activity, (ii) wider spectra, and (iii) higher selectivity and specificity than Imatinib mesylate (Gleevec), which is one of the most frequently used chemotherapeutical molecular targeting anti-tumour agent.

• Periodical: Advanced Materials Research (Volume 222)
• Pages: 217-220
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.222.217
• Online since: April 2011
• Authors: Keita Kiyofuji, Kenji Tsunekawa, Mitsuji Yamashita, Junko Yamashita, Michio Fujie, Kazuhide Asai, Takuya Suyama, Satoru Ito, Valluru Krishna Reddy, Manabu Yamada, Keisuke Ogawa, Nobuhisa Ozaki, Masaki Sugiyama, Mayumi Yamaoka, Reiko Makita, Satoki Nakamura, Takashi Aoki, Gang Yu, Kengo Aoshima, Nao Kamikage, Yasuo Takehara, Harumi Sakahara, Hisao Takayanagi, Sophie Laurent, Carmen Burtea, Luce Vander Elst, Robert N. Muller
• Keywords: Anti-Leukemia Agent, Cancer Diagnosis, Deoxybromophospha Sugars, MR Angiography (MRA), MRI Contrast Agent, MTT In Vitro Evaluation, Phosphorus Heterocycles, Sugar Ball Dendritic Gd-DTPA Complex

References

[1] M. Takahashi, Y. Hara, K. Aoshima, H. Kurihara, T. Oshikawa, and M. Yamashita: Tetrahedron Lett., Vol. 41 (2000) 8485.

[2] H. Lammers, F. Maton, D. Pubanz, M. W. Van Laren, H. Van Bekkum, A. E. Merbach, R. N. Muller, and J. A. Peters: Inorg. Chem., Vol. 36 (1997) 2527.

DOI: 10.1021/ic961359k

[3] M. Yamashita, V. K. Reddy, L. N. Rao, B. Haritha, M. Maeda, K. Suzuki, H. Totsuka, M. Takahashi, and T. Oshikawa: Tetrahedron Lett., Vol. 44 (2003) 2339.

DOI: 10.1016/s0040-4039(03)00255-7

[4] H. Totsuka, M. Maeda, V. K. Reddy, M. Takahashi, and M. Yamashita: Heterocyclic Commun., Vol. 10 (2004) 295.

[5] S. Nakamura, M. Yamashita, D. Yokota, I. Hirano, T. Ono, M. Fujie, K. Shibata, T. Niimi, T. Suyama, K. Maddali, H. Asai, J. Yamashita, Y. Iguchi, and K. Ohnishi: Investigational New Drugs, Vol. 28 (2010) 381.

DOI: 10.1007/s10637-009-9255-3